Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTX-HSA-FA
- Development stage
- Preclinical
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
DTX-HSA-FA is a folate-targeted nanoparticle formulation of docetaxel conjugated to human serum albumin (HSA) and decorated with folic acid (FA). Developed by researchers at the Tehran University of Medical Sciences, the conjugate is designed to improve the water solubility of docetaxel and actively target cancer cells that overexpress folate receptors. By utilizing folic acid as a targeting ligand, the nanoparticles are selectively internalized by folate receptor-positive cancer cells, enhancing cytotoxicity and reducing systemic side effects. Preclinical in vitro and in vivo studies have demonstrated superior tumor reduction and survival rates compared to free docetaxel in breast cancer models.
- Other names
- docetaxel-human serum albumin-folic acid conjugatedocetaxel-human serum albumin-folic acid nanoparticlesfolate-decorated human serum albumin nanoparticles of docetaxelfolic acid-human serum albumin-docetaxel conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))FOLR1 (FRα)
Beyond the preview
Go deeper on DTX-HSA-FA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTX-HSA-FA.